Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 3/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329285 | 0.79 | MEN1 (0.50) | NPC1RAB9A | |
| SCHEMBL691154 | 0.79 | KDM4E (0.44) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL18806864 | 0.75 | CYP1A2 (0.61) | CYP1A2MAPTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL30674461 | 0.75 | CYP1A2 (0.58) | CYP1A2MAPTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL28583381 | 0.75 | CYP1A2 (0.58) | CYP1A2MAPTALDH1A1SMN1; SMN2MAOA | |
| SCHEMBL28572207 | 0.75 | CYP1A2 (0.57) | CYP1A2MAPTSMN1; SMN2MAOAMAOB | |
| SCHEMBL28613677 | 0.73 | CYP1A2 (0.52) | CYP1A2MAPTALDH1A1SMN1; SMN2L3MBTL1 | |
| SCHEMBL7112190 | 0.73 | ALDH1A1 (0.48) | MAPTALDH1A1ATMGAAKDM4E | |
| SCHEMBL347520 | 0.73 | BRD4 (0.47) | — | |
| SCHEMBL28573822 | 0.71 | CYP1A2 (0.54) | CYP1A2MAOAMAOBPDE10ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | RESVERLOGIX CORP (CA) | 2016-12-01 | — | — | US | disclosed |
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| WO-2013156869-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281397-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | BRD4, BMI1, BRPF3 | CYP1A2 4781/4885MAPT 2454/4885ALDH1A1 4671/4885 |
| US-20160346291-A1 | COMPOSITIONS AND THERAPEUTIC METHODS FOR ACCELERATED PLAQUE REGRESSION | PCSK9, TGFB1, HMGCR | CYP1A2 4357/4885MAPT 256/4885ALDH1A1 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.